278 related articles for article (PubMed ID: 22908151)
1. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.
Noel GJ; Draper MP; Hait H; Tanaka SK; Arbeit RD
Antimicrob Agents Chemother; 2012 Nov; 56(11):5650-4. PubMed ID: 22908151
[TBL] [Abstract][Full Text] [Related]
2. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
5. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
[TBL] [Abstract][Full Text] [Related]
6. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
[TBL] [Abstract][Full Text] [Related]
7. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
Weigelt J; Itani K; Stevens D; Lau W; Dryden M; Knirsch C;
Antimicrob Agents Chemother; 2005 Jun; 49(6):2260-6. PubMed ID: 15917519
[TBL] [Abstract][Full Text] [Related]
8. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
9. Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease.
Duane TM; Weigelt JA; Puzniak LA; Huang DB
Surg Infect (Larchmt); 2012 Jun; 13(3):147-53. PubMed ID: 22568921
[TBL] [Abstract][Full Text] [Related]
10. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Puzniak LA; Morrow LE; Huang DB; Barreto JN
Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
[TBL] [Abstract][Full Text] [Related]
11. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
[TBL] [Abstract][Full Text] [Related]
12. Linezolid for the treatment of complicated skin and skin structure infections in children.
Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
[TBL] [Abstract][Full Text] [Related]
13. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
Prokocimer P; Bien P; Surber J; Mehra P; DeAnda C; Bulitta JB; Corey GR
Antimicrob Agents Chemother; 2011 Feb; 55(2):583-92. PubMed ID: 21115795
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.
Stevens DL; Smith LG; Bruss JB; McConnell-Martin MA; Duvall SE; Todd WM; Hafkin B
Antimicrob Agents Chemother; 2000 Dec; 44(12):3408-13. PubMed ID: 11083648
[TBL] [Abstract][Full Text] [Related]
15. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection.
Covington P; Davenport JM; Andrae D; O'Riordan W; Liverman L; McIntyre G; Almenoff J
Antimicrob Agents Chemother; 2011 Dec; 55(12):5790-7. PubMed ID: 21947389
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
19. Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.
Pfaller MA; Rhomberg PR; Huband MD; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993854
[TBL] [Abstract][Full Text] [Related]
20. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
